Introduction
Boehringer Ingelheim has initiated a Phase IIa clinical trial for BI 765423, a monoclonal antibody targeting interleukin-11 (IL-11), in patients with idiopathic pulmonary fibrosis (IPF). This marks a significant step in addressing progressive fibrotic lung diseases.
IPF Overview
IPF is a progressive lung disease affecting over three million people worldwide, characterized by worsening breathlessness and declining lung function. It has a lower five-year survival rate than several cancers, with half of patients succumbing within five years of diagnosis. Current treatments slow progression but do not halt lung function decline or reverse scarring, highlighting a high unmet need.
BI 765423 Mechanism
BI 765423 is designed to bind directly to IL-11, blocking its interaction with its receptor and interrupting fibrosis-causing signaling pathways. Pre-clinical studies indicate that anti-IL-11 treatment can halt fibrosis and restore lung function and tissue integrity.
Clinical Trials
Phase I studies showed BI 765423 has a favorable safety and tolerability profile in healthy volunteers. The Phase IIa study will be the first to evaluate its efficacy in IPF patients. BI 765423 is an acquired asset from Enleofen, with in-licensed intellectual property from Singapore Health Services and the National University of Singapore.
